QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
QQQ   303.46 (+1.28%)
AAPL   122.72 (+3.08%)
MSFT   216.21 (+1.00%)
FB   286.55 (+3.46%)
GOOGL   1,795.36 (+2.33%)
AMZN   3,220.08 (+1.64%)
TSLA   584.76 (+3.02%)
NVDA   535.60 (-0.09%)
BABA   264.01 (+0.25%)
CGC   26.65 (-7.47%)
GE   10.15 (-0.29%)
MU   67.08 (+4.67%)
AMD   92.63 (-0.03%)
T   28.87 (+0.42%)
NIO   45.36 (-10.23%)
F   9.24 (+1.76%)
ACB   9.75 (-16.52%)
NFLX   504.58 (+2.83%)
BA   213.01 (+1.09%)
GILD   61.12 (+0.74%)
DIS   149.44 (+0.97%)
Log in
NASDAQ:CRTX

Cortexyme Stock Forecast, Price & News

$49.22
+0.62 (+1.28 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$47.30
Now: $49.22
$50.89
50-Day Range
$44.28
MA: $49.59
$56.93
52-Week Range
$26.99
Now: $49.22
$73.84
Volume119,224 shs
Average Volume130,823 shs
Market Capitalization$1.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.38
Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:CRTX
CUSIP21924P10
Phone(650) 910-5717
Employees23

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.37 per share

Profitability

Net Income$-36,980,000.00

Miscellaneous

Market Cap$1.45 billion
Next Earnings Date3/16/2021 (Estimated)
OptionableNot Optionable
$49.22
+0.62 (+1.28 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

How has Cortexyme's stock price been impacted by COVID-19 (Coronavirus)?

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 33.0% and is now trading at $49.22.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cortexyme?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cortexyme
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cortexyme?

Wall Street analysts have given Cortexyme a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cortexyme wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release its next quarterly earnings announcement on Tuesday, March 16th 2021.
View our earnings forecast for Cortexyme
.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) posted its quarterly earnings results on Tuesday, November, 17th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.11.
View Cortexyme's earnings history
.

What price target have analysts set for CRTX?

4 analysts have issued 1-year price targets for Cortexyme's stock. Their forecasts range from $59.00 to $76.00. On average, they anticipate Cortexyme's stock price to reach $68.33 in the next year. This suggests a possible upside of 38.8% from the stock's current price.
View analysts' price targets for Cortexyme
.

Are investors shorting Cortexyme?

Cortexyme saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,990,000 shares, an increase of 26.8% from the October 31st total of 1,570,000 shares. Based on an average daily volume of 110,100 shares, the days-to-cover ratio is currently 18.1 days. Currently, 16.5% of the shares of the company are sold short.
View Cortexyme's Short Interest
.

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

Who are Cortexyme's key executives?

Cortexyme's management team includes the following people:
  • Casey Crawford Lynch, Chairman, President & Chief Executive Officer
  • Christopher P. Lowe, CFO, Treasurer & Principal Accounting Officer
  • Stephen S. Dominy, Chief Scientific Officer & Director
  • Leslie J. Holsinger, Executive Vice President-Research & Development
  • Michael J. Detke, Chief Medical Officer

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by a number of institutional and retail investors. Top institutional investors include EPIQ Capital Group LLC (11.58%), BlackRock Inc. (3.26%), State Street Corp (0.97%), Pacific Heights Asset Management LLC (0.76%), Charles Schwab Investment Management Inc. (0.31%) and SG Americas Securities LLC (0.19%). Company insiders that own Cortexyme stock include David Lamond, Epiq Capital Group, Llc and Pfizer Inc.
View institutional ownership trends for Cortexyme
.

Which institutional investors are selling Cortexyme stock?

CRTX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Natixis, Victory Capital Management Inc., Wells Fargo & Company MN, Alps Advisors Inc., Alps Advisors Inc., Morgan Stanley, and Letko Brosseau & Associates Inc..
View insider buying and selling activity for Cortexyme
.

Which institutional investors are buying Cortexyme stock?

CRTX stock was purchased by a variety of institutional investors in the last quarter, including EPIQ Capital Group LLC, Pacific Heights Asset Management LLC, BlackRock Inc., Charles Schwab Investment Management Inc., SG Americas Securities LLC, Schonfeld Strategic Advisors LLC, Jane Street Group LLC, and Boothbay Fund Management LLC. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc.
View insider buying and selling activity for Cortexyme
.

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $49.22.

How big of a company is Cortexyme?

Cortexyme has a market capitalization of $1.45 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 23 workers across the globe.

What is Cortexyme's official website?

The official website for Cortexyme is www.cortexyme.com.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 910-5717 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.